ClinicalTrials.gov
public full text
Public Domain
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer#1103524
- Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer.#30825
- Table 1_The role of molecular profiling for castration-resistant prostate cancer treatment and therapy development.docx#471743
- Atrasentan Spermatogenesis and Testicular Function#127797
- Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency#1088533
Record · ID 915850
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive